Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
1181-1200 of 2,251 trials

Prostate Cancer: Radium-223 and Docetaxel Study

We are exploring whether using Radium-223 followed by Docetaxel helps men with bone-only metastatic prostate cancer feel better and live longer. This study will compare the effects of these treatments on quality of life and survival.

Metastatic Castration-Resistant Prostate CancerSymptomatic Bone-Only Metastatic Castration-Resistant Prostate Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyUrology

NVDX3 Implant: Long-Term Safety Study

We are examining the long-term safety of the NVDX3 osteogenic implant made from human tissue. This study aims to ensure it is safe for patients who may need this type of treatment.

Low Grade Degenerative Lumbar SpondylolisthesisDistal Radius Fracture>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOrthopedics and Traumatology

Bronchiectasis: 7% Hypertonic Saline Inhalation

We are studying whether inhaling a 7% hypertonic saline solution before physiotherapy helps patients with bronchiectasis clear mucus more effectively. We’ll also look at its impact on cough, quality of life, and any side effects.

Bronchiectasis1-2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboInvestigational MedicinesInternal MedicinePulmonology

Long-term Safety of Genetically Modified T Cell Therapy

We are following up with patients who received genetically modified T cells to assess their long-term safety and survival. This study aims to understand how well the treatment works and any potential risks involved.

Acute Lymphoblastic LeukemiaSystemic Lupus ErythematosusNon-Hodgkin's Lymphoma>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyOncologyRheumatology

Myelofibrosis: Testing RVU120

We are studying the investigational drug RVU120 for patients with myelofibrosis to see if it helps reduce cancer symptoms and improve treatment outcomes. This trial will also assess its safety and effectiveness when used alone or with another medication.

MyelofibrosisEfficacy phase (II)No PlaceboInvestigational MedicinesHematology

Dexamethasone for Congenital Adrenal Hyperplasia in Pregnancy

We are studying whether a lower dose of dexamethasone can effectively prevent prenatal complications in female babies with congenital adrenal hyperplasia. We will also monitor the health of mothers and their children during and after pregnancy.

Congenital Adrenal HyperplasiaEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteEndocrinologyGynecology and Obstetrics

High Blood Pressure: Irbesartan and Amlodipine Combination

We are testing a new fixed-dose pill combining irbesartan and amlodipine for patients with high blood pressure. The goal is to see if it effectively lowers blood pressure and is safe for use.

High Blood Pressure1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Stage III Lung Cancer: Surgery and Durvalumab Study

We are exploring whether surgery is safe for patients with initially unresectable stage III lung cancer after high-dose treatment. We also want to see if they can benefit from a follow-up therapy called durvalumab.

Stage III Non-Small Cell Lung CancerMonitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteOncologyPulmonology

Enterococcus faecalis Endocarditis: Continuous Infusion Antibiotics Study

We are studying whether continuous infusion of ampicillin and ceftriaxone is as effective as standard treatment for patients with Enterococcus faecalis infective endocarditis. This may help improve treatment outcomes and reduce complications.

Enterococcal Endocarditis>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInfectious Diseases

Adnexal Torsion: Contrast-Enhanced Ultrasound Study

We are testing a new ultrasound method to see if it helps diagnose adnexal torsion more accurately than standard methods. This could reduce unnecessary surgeries and improve care for patients with suspected torsion.

Adnexal Torsion>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteGynecology and ObstetricsInternal Medicine

Ovarian Cancer: Olaparib and Durvalumab Study

We are exploring whether Olaparib alone or with Durvalumab can be safely given to patients with high-grade ovarian cancer before surgery. This study may help us learn more about treatment effectiveness and safety.

Ovarian Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

Liver Fibrosis Assessment: 68Ga-FAPI Imaging Study

We are studying a new imaging technique to evaluate liver fibrosis in patients with suspected nonalcoholic steatohepatitis. This may help improve the accuracy of liver damage assessments compared to standard methods.

Non-Alcoholic Steatohepatitis (NASH)>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesGastroenterologyHepatologyInternal Medicine

Heart Attack Treatment: Timing of Medications

We are studying how the timing of beta blockers, ACE inhibitors, and SGLT2 inhibitors affects heart function in people who have had a heart attack. This may help us understand the best way to use these medications for better recovery.

Heart Attack>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine

Advanced NSCLC: NVL-520 Treatment Study

We are testing a new medication, NVL-520, for patients with advanced ROS1-positive solid tumors, including non-small cell lung cancer. The study aims to find the best dose and evaluate its effectiveness and safety.

Advanced ROS1-positive Lung CancerSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Danicopan for Pediatric PNH Patients

We are studying whether adding danicopan to existing treatments helps children with Paroxysmal Nocturnal Hemoglobinuria improve their hemoglobin levels and quality of life.

Paroxysmal Nocturnal Hemoglobinuria3-6 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHematologyPediatrics

Cardiogenic Shock: Beta Receptor Modulation Trial

We are testing a new approach to manage heart function in patients with cardiogenic shock on V-A ECMO. This study compares reducing beta receptor stimulation to the usual treatment to see which is safer and more effective.

Cardiogenic Shock>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCardiologyInternal Medicine

Duchenne Muscular Dystrophy: Givinostat Study for Young Boys

We are studying the safety and effects of givinostat in boys aged 2 to under 6 years with Duchenne Muscular Dystrophy. This trial aims to understand how the drug works in their bodies and its impact on muscle function.

Duchenne Muscular DystrophyEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesNeurologyOrthopedics and Traumatology

Cognitive Disorders: BioFINDER 2 Study

We are investigating new imaging methods to better diagnose Alzheimer's disease in healthy older adults and those with early cognitive symptoms. The goal is to understand brain changes that may lead to dementia.

Dementia and Neurodegenerative Disorders>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteInternal MedicineNeurology

Relapsed Multiple Myeloma: Daratumumab Treatment Study

We are comparing two treatment strategies using Daratumumab, Lenalidomide, and Dexamethasone for patients with relapsed multiple myeloma. The goal is to see if a fixed treatment duration is as effective as continuous therapy.

Myeloma Recurrence>2 yearsConfirmation phase (III)>20 visitsNo PlaceboStandard MedicinesHematologyOncology

Baricitinib for Calcium Pyrophosphate Disease

We are studying whether Baricitinib can reduce inflammation and improve symptoms in people with calcium pyrophosphate dihydrate deposition disease. This trial will help us understand its effects on pain and inflammation.

Calcium Pyrophosphate Deposition Disease3-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineRheumatology